Pharmaceuticals, Biotechnology and Life Sciences
Trovagene will present new clinical data from its Phase 2 trial of onvansertib, in combination with Zytiga (abiraterone acetate)/prednisone, in…
Dr. Mark Erlander, Chief Scientific Officer of Trovagene. “We believe the positive results of our preclinical study provides the scientific rationale for clinical investigation of this combination regimen and may lead to a new treatment option for these patients.”
Trovagene said that additional data from its ongoing Phase 1b/2 study of onvansertib combined with standard-of-care chemotherapy in Acute Myeloid…
Trovagene has expanded the use of Onvansertib to enable it for combination therapies with anti-androgen drugs, like Zytiga, Xtandi and Erledea to treat castrate-resistant prostate cancer.